The Nationwide Real-world Status of Oral Corticosteroid Use in Patients With Asthma

Study Overview
=================
Brief Summary
-----------------
The Health Insurance Review and Assessment Service (HIRA) database contains nationwide claim data. By utilizing this database, the investigators aimed to analyze the current status of OCS use in South Korea by using HIRA database.

Detailed Description
-----------------
South Korea has a compulsory universal health insurance system for entire Korean population. The number of people who are covered was more than 50 million. The Health Insurance Review and Assessment Service (HIRA) database contains nationwide claim data. By utilizing this database, the investigators have performed many studies regarding asthma in South Korea. In this study, the investigators aimed to analyze the current status of OCS use in South Korea by using HIRA database. Primary outcome was the OCS prescription in all patients with asthma. Secondary outcome was OCS prescription according to the asthma severity, age, sex, socioeconomic status and the type of hospital. Inclusion criteria was 1) Age ≥ 15 years; 2) ICD-10 codes for asthma (J45.x-J46) as the primary or within fourth secondary diagnosis; 3) use of more than one drug for asthma at least twice per year (long acting muscarinic antagonist (LAMA), long acting beta2 agonist (LABA), ICS, ICS+LABA, short acting muscarinic antagonist (SAMA), short acting beta2 agonist (SABA), SAMA+SABA, theophylline, leukotriene antagonist, systemic corticosteroids, or systemic beta agonist).

Official Title
-----------------
The Nationwide Real-world Status of Oral Corticosteroid Use in Patients With Asthma

Conditions
-----------------
Asthma, Corticosteroid

Intervention / Treatment
-----------------
* Drug: Oral corticosteroids


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 15 years; ICD-10 codes for asthma (J45.x-J46) as the primary or within fourth secondary diagnosis use of more than one drug for asthma at least twice per year (long acting muscarinic antagonist (LAMA), long acting beta2 agonist (LABA), ICS, ICS+LABA, short acting muscarinic antagonist (SAMA), short acting beta2 agonist (SABA), SAMA+SABA, theophylline, leukotriene antagonist, systemic corticosteroids, or systemic beta agonist). Exclusion Criteria: • Those who are not in the insurance system

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Oral corticosteroids|The prescription of OCS will be analyzed. OCS included betamethasone, deflazacort, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, and triamcinolone.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OCS prescription rates | Analysis the OCS prescription in all patients with asthma | 1-year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OCS prescription according to the asthma severity |  | 1-year | 
| OCS prescription according to age |  | 1-year | 
| OCS prescription according to sex |  | 1-year | 
| OCS prescription according to socioeconomic status |  | 1-year | 
| OCS prescription according to the type of hospital |  | 1-year |